Key result
Percutaneous transluminal myocardial revascularization using a holmium:YAG laser safely reduced mean angina class from 3.68 to 1.08 at 6 months (P<0.01) in patients with refractory angina.
Why the study?
Does percutaneous transluminal myocardial revascularization with a holmium:YAG laser improve angina symptoms in patients with refractory angina not amenable to standard revascularization?
Observational (n=35)
Does percutaneous transluminal myocardial revascularization with a holmium:YAG laser improve angina symptoms in patients with refractory angina not amenable to standard revascularization?
Percutaneous transluminal myocardial revascularization with a holmium:YAG laser appears safe and provides significant early symptomatic relief in patients with refractory angina unsuitable for standard revascularization.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in refractory angina; leaves open efficacy of PTMR with holmium:YAG laser.
Surgical transmyocardial laser revascularization has been reported to improve clinical outcome in patients with refractory angina who are not candidates for angioplasty or bypass surgery. We investigated the feasibility and safety of a nonsurgical, percutaneous technique for laser channel creation using energy from a holmium:yttrium-aluminium-garnet (YAG) laser. The laser energy was directed through a fiber enclosed in a catheter to the ventricular myocardium creating channels between the blood pool and the myocardium. Thirty-five patients with angina and coronary anatomy not amenable to revascularization with coronary angioplasty or bypass surgery underwent percutaneous transluminal myocardial revascularization. A total of 15 +/- 5 channels were formed per patient. There was no procedure-related mortality. One patient developed cardiac tamponade requiring thoracotomy and another a minor self-limiting pericardial effusion. There was no worsening of regional wall motion function in any patient. All patients were discharged alive after a postprocedure hospital stay of 2.1 +/- 1.4 days. Mean Canadian Cardiovascular Society (CCS) functional class declined from 3.68 +/- 0.4 before procedure to 0.82 +/- 0.7 at 30 days (P < 0.01). At 3 months, mean angina class was 0.94 +/- 0.65 (n = 35; P < 0.01) and at 6 months, mean angina class was 1.08 +/- 0.58 (n = 26; P < 0.01). One patient required repeat revascularization after 5 months for progression of disease in a degenerated saphenous venous graft supplying different region of myocardium. We conclude that transmyocardial revascularization using holmium:YAG laser by percutaneous technique can be carried out safely with encouraging early results and a very low complication rate. The symptomatic relief seen up to 6 months has been excellent. The long-term effects of this technique on mortality and relief of angina, however, remain to be defined. Cathet. Cardiovasc. Intervent. 47:287-291, 1999.
No takes yet. Share an insight, caveat, or question.
Kaul et al. (1999) conducted an observational in Refractory angina (n=35). Percutaneous transluminal myocardial revascularization with holmium:YAG laser was evaluated on Canadian Cardiovascular Society (CCS) functional class (p=<0.01). Percutaneous transluminal myocardial revascularization using a holmium:YAG laser safely reduced mean angina class from 3.68 to 1.08 at 6 months (P<0.01) in patients with refractory angina.
Synapse has enriched 10 related papers. Consider them for comparative context: